Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Azitra Inc. (NYSE American: AZTR), a precision dermatology company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. Travis Whitfill, the company's COO, will present an overview of Azitra at the conference.
Key details:
- The on-demand presentation will be available from September 9, 2024, at 7:00 a.m. ET
- Company management will participate in one-on-one meetings during the event
- The presentation will be held at the Lotte New York Palace Hotel, New York City
- An archived replay will be available on Azitra's website for at least 30 days after the conference
This presentation offers investors an opportunity to gain insights into Azitra's operations and future prospects in the precision dermatology field.
Azitra Inc. (NYSE American: AZTR), un'azienda specializzata in dermatologia di precisione, ha annunciato la sua partecipazione al 26° Annual Global Investment Conference di H.C. Wainwright, che si svolgerà dal 9 all'11 settembre 2024. Travis Whitfill, COO dell'azienda, presenterà una panoramica di Azitra alla conferenza.
Dettagli principali:
- La presentazione on-demand sarà disponibile dal 9 settembre 2024, alle 7:00 a.m. ET
- La direzione aziendale parteciperà a incontri individuali durante l'evento
- La presentazione avrà luogo presso il Lotte New York Palace Hotel, New York City
- Una registrazione archiviata sarà disponibile sul sito web di Azitra per almeno 30 giorni dopo la conferenza
Questa presentazione offre agli investitori l'opportunità di ottenere informazioni sulle operazioni di Azitra e sulle prospettive future nel campo della dermatologia di precisione.
Azitra Inc. (NYSE American: AZTR), una empresa de dermatología de precisión, ha anunciado su participación en la 26ª Conferencia Anual de Inversión Global de H.C. Wainwright del 9 al 11 de septiembre de 2024. Travis Whitfill, COO de la empresa, presentará una visión general de Azitra en la conferencia.
Detalles clave:
- La presentación bajo demanda estará disponible a partir del 9 de septiembre de 2024, a las 7:00 a.m. ET
- La dirección de la empresa participará en reuniones individuales durante el evento
- La presentación se llevará a cabo en el Lotte New York Palace Hotel, Ciudad de Nueva York
- Una repetición archivada estará disponible en el sitio web de Azitra durante al menos 30 días después de la conferencia
Esta presentación ofrece a los inversores una oportunidad de obtener información sobre las operaciones y las perspectivas futuras de Azitra en el campo de la dermatología de precisión.
Azitra Inc. (NYSE American: AZTR), 정밀 피부과 전문 회사,가 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 2024년 9월 9일부터 11일까지 참여한다고 발표했습니다. 트래비스 휘틀필, 회사 COO가 컨퍼런스에서 Azitra의 개요를 발표할 예정입니다.
주요 사항:
- 온디맨드 발표는 2024년 9월 9일 오전 7:00 ET부터 이용 가능
- 회사 경영진이 행사 중 일대일 미팅에 참여할 예정
- 발표는 뉴욕시의 Lotte New York Palace Hotel에서 진행됩니다
- 아카이브 재생은 컨퍼런스 후 최소 30일 동안 Azitra의 웹사이트에서 이용 가능합니다
이번 발표는 투자자들에게 정밀 피부과 분야에서 Azitra의 운영 및 미래 전망에 대한 통찰을 제공할 기회를 제공합니다.
Azitra Inc. (NYSE American: AZTR), une entreprise spécialisée en dermatologie de précision, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale d'Investissement de H.C. Wainwright qui se tiendra du 9 au 11 septembre 2024. Travis Whitfill, directeur des opérations de l'entreprise, présentera un aperçu d'Azitra lors de la conférence.
Détails clés :
- La présentation à la demande sera disponible à partir du 9 septembre 2024, à 7h00 ET
- La direction de l'entreprise participera à des réunions individuelles pendant l'événement
- La présentation se déroulera au Lotte New York Palace Hotel, à New York
- Un replay archivé sera disponible sur le site d'Azitra pendant au moins 30 jours après la conférence
Cette présentation offre aux investisseurs l'occasion d'obtenir des informations sur les opérations d'Azitra et ses perspectives d'avenir dans le domaine de la dermatologie de précision.
Azitra Inc. (NYSE American: AZTR), ein Unternehmen für präzise Dermatologie, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright vom 9. bis 11. September 2024 bekannt gegeben. Travis Whitfill, COO des Unternehmens, wird auf der Konferenz einen Überblick über Azitra präsentieren.
Wichtige Details:
- Die Präsentation auf Abruf wird ab dem 9. September 2024 um 7:00 Uhr ET verfügbar sein
- Das Management des Unternehmens wird während der Veranstaltung an Einzeltreffen teilnehmen
- Die Präsentation findet im Lotte New York Palace Hotel in New York City statt
- Eine archivierte Wiederholung wird für mindestens 30 Tage nach der Konferenz auf der Website von Azitra verfügbar sein
Diese Präsentation bietet Investoren die Möglichkeit, Einblicke in die Abläufe und Zukunftsperspektiven von Azitra im Bereich der präzisen Dermatologie zu gewinnen.
- None.
- None.
The on-demand presentation will be available for viewing beginning September 9 at 7:00 a.m. ET. An archived replay of the presentation will be available on the Company’s website immediately following the conference and for at least 30 days thereafter.
H.C. Wainwright 26th Annual Global Investment Conference – September 9-11, 2024
Format: Azitra Inc., Corporate Presentation
Date/Time: Available on-demand Monday, September 9, 2024 at 7:00 AM ET
Participant: Travis Whitfill, Chief Operating Officer
Location: Lotte New York Palace Hotel,
Webcast Link: Here
About Azitra, Inc.
Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the Company's library of strains for drug like molecules. The Company's initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the Company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies. For more information, please visit https://azitrainc.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described and incorporated by reference more fully in the section titled “Risk Factors” in our Form 10-Q filed with the SEC on August 12, 2024. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240906297209/en/
Investor Relations Contact:
Norman Staskey
Chief Financial Officer
staskey@azitrainc.com
Hayden IR
James Carbonara
(646) 755-7412
james@haydenir.com
Source: Azitra, Inc.
FAQ
When is Azitra (AZTR) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Azitra (AZTR) at the H.C. Wainwright conference?
Where can investors view Azitra's (AZTR) presentation from the H.C. Wainwright conference?
What type of meetings will Azitra (AZTR) participate in during the H.C. Wainwright conference?
